EP072/#875 Patient-derived organoids as a preclinical platform for precision medicine in patients with cervical cancer

Objectives

To date, scant attention has been paid to patient-derived organoids of cervical cancer, even though organoids have been utilized to study of patient-specific cancer therapy. The purpose of this study was to establish cervical cancer-derived organoids (CCO) and assess the ability to predict response to radiation.

Methods

Cervical tissue samples from therapy-naive cervical cancer patients diagnosed between May 2019 and April 2022 were obtained. Based on our long-term culturing protocol, we established various types of CCOs, such as Squamous cell carcinoma (SCC), adenocarcinoma (AC), and neuroendocrine carcinoma (NEC). Using CCOs, we assessed the radiosensitivity in a suitable preclinical manner.

Results

We successfully generated CCOs in 15 of 30 cancer tissues (50%), of which were SCC (60.0%), AC (33.3%), and NEC (6.7%). The success rate of establishing CCOs varied with cell types; 45.0% and 83.3% for SCC and AC, respectively. Additionally, a radiation sensitivity test was performed on 4 different cell types of organoids: SCC, AC, NEC, and Villoglandular papillary adenocarcinoma (VPA). After exposure to radiation (0, 2, 6, and 12Gy) and culture for 7 days, dramatical apoptotic cell death was confirmed especially in SCC and VPA organoids, whereas less apoptotic cell death was observed in AC.

Conclusions

Patients-derived cervical cancer organoid have been successfully created and can recapitulate the patients tumor. This is a first study to date that explored the effects of radiosensitivity in patient-derived organoids in cervical cancer. Organoids could serve as a useful preclinical platform to implement of personalized therapy including radiotherapy in cervical cancer patients.